Clinical Trial Detail

NCT ID NCT02158507
Title Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors University of Alabama at Birmingham, Scariot Foundation, GlaxoSmithKline, AbbVie
Indications

triple-receptor negative breast cancer

Therapies

Lapatinib + Veliparib

Age Groups: adult

No variant requirements are available.